Smiths Medical received FDA regulatory approval for its CADD-Solis pain management system version 3.0 with Programmed Intermittent Bolus (PIB) and Patient Controlled Analgesics (PCA) delivery. The system is aimed to improve delivery of epidural analgesia during child birth and for post-operative pain management.
The CADD-Solis pump features a large color screen that displays all the relevant information, including the current bolus interval and when the next infusion is schedule for. It records activity and sounds alarms when pre-set parameters are exceeded and works off of task-based software and an embedded therapy-based drug protocol library.
From Smiths Medical:
The CADD®-Solis ambulatory infusion system is a state-of-the-art pain management system that meets industry recognized standards for advanced error-reduction features in PCA pumps. The CADD®-Solis pump and medication safety software promotes patient safety, patient care, and future scalable connectivity that is designed to grow with evolving clinical and technology needs. The platform is designed for nurses, anesthesiologists, pharmacists and other hospital personnel involved in pain management infusion therapy who want the confidence of knowing they are delivering the highest level of patient care, with the most advanced combination of SMART medication delivery safety, mobility, versatility and reliability.
“The new CADD®-Solis system with PIB and PCA combines programmed intermittent boluses and patient-controlled doses in an integrated, innovative delivery system,” said Tommy Johns, Vice President Global Product Management. “The PIB programming parameters and the delivery pressure provided by the CADD®-Solis system offer flexible drug delivery and reliable distribution of medication, which can help overcome some of the challenges associated with epidural analgesia.”